// App-Quantinova.ai

: Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience

Researchers

Presenter

  • Marie-Anne Couturier

Principal Investigators

  • Xavier Thomas

  • Francoise Huguet

  • Cline Berthon

  • Clestine Simand

  • Yosr Hicheri

  • Mathilde Hunault

  • Patrice Chevallier

Medical Centers

  • department of hematology, CHRU Brest, BREST, France

  • Lyon Sud Hospital, MBJ, Pierre-Benite, France

  • Dermatology department, Institut Universitaire du Cancer de Toulouse et CHU de Toulouse, Toulouse, France

  • Hematology, CHRU Lille, Lille, France

  • Department of hematology, CHU de Hautepierre, Strasbourg, France

  • Department of Clinical Hematology, Montpellier University Hospital, Montpellier, France

  • Department of Hematology,CHU Angers,Angers,France

  • Pediatric Hematology, Nantes University Hospital, Nantes, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

Drug/Treatment

  • Blinatumomab

  • Ponatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved